FirstMark, a diagnostic division of GenWay Biotech, has introduced a cardiovascular diagnostic blood test - PREvent and also presented its study results.
PREvent is a multiple biomarker test which is designed to predict near term (approximately 2-3 years) risk of multiple pathways that lead to myocardial infarction (MI) for suspected or confirmed coronary artery disease (CAD) patients.
The Phase I and phase II clinical studies enrolled approximately 3,000 individuals with suspected or confirmed CAD.
The studies results demonstrated that PREvent is more powerful than other tests and risk factors, by identifying the top 10% of confirmed CAD patients with all three biomarkers elevated and are at a 6.45 times higher risk of a near term MI within a 2-3 year period.
GenWay Biotech president and CEO Thomas Silberg said this simple blood test is an exciting development for suspected or confirmed CAD patients, allowing physician’s diagnostic clarity in identifying CAD patients that are in most urgent need of aggressive treatment and monitoring.